Non-CYP Mediated Metabolism
Monoamine Oxidase (MAO) Inhibition Assay
Understand if your compound is an inhibitor of MAO-A or MAO-B enzyme.
Monoamine oxidase (MAO) inhibition is a non-CYP mediated inhibition assay within our portfolio of in vitro ADME screening services. Cyprotex delivers consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.
Introduction
Determining potential inhibition of MAO enzymes:
- Monoamine oxidases (MAO) are membrane-associated enzymes located specifically on the outer mitochondrial membrane. They are the major enzymes participating in the catabolism of monoamine neurotransmitters and related exogenous amines.
- Two isoforms of MAO exist, MAO-A and MAO-B, which differ in their substrate specificity, inhibitor selectivity and tissue distribution.
- Selective MAO-A inhibitors are useful in the therapy of depression and anxiety whereas MAO-B inhibitors are often used in the treatment of Parkinson’s and Alzheimer’s diseases.
- Cyprotex’s MAO inhibition assay identifies if your compound is an inhibitor for either MAO-A or MAO-B.
Protocol
Monoamine Oxidase Inhibition Assay Protocol
Data
Data from the Monoamine Oxidase Inhibition Assay
Downloads
- Cyprotex ADME Guide 5th Edition >
- Cyprotex DDI Regulatory Guide 3rd Edition >
- Cyprotex Monoamine Oxidase Inhibition Assay Factsheet >
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.
